Add‐on effect of Qiming granule, a Chinese patent medicine, in treating diabetic macular edema: A systematic review and meta‐analysis

This study aims to evaluate the efficacy and safety of Qiming granule (QG) on diabetic macular edema (DME). PubMed, Embase, the Cochrane Library, CNKI, Wanfang, qvip and China Biology Medicine Disc were searched. Randomized controlled trials (RCTs) about participants with a diagnosis of DME were included. Risk of bias assessment was conducted by Cochrane risk‐of‐bias tool for RCT. Random‐effects model was implemented to pool results. Among 16 included studies, QG combined with conventional treatment was administered 13.5 g daily for a period ranging from 2 to 6 months. Results showed combination therapy was more effective than conventional treatment alone in central macular thickness (weighted mean difference (WMD) = −29.43, 95% confidence interval (CI) (−39.56 to −19.29), p = .0001), optimum corrected vision (pooled standardized mean difference (SMD) = −0.962, 95%CI (−1.35 to −0.57), p = .0001) and overall effective rate (RR = 1.25, 95%CI = [1.13 to 1.35], p < .0001). Only three studies reported adverse effects. The quality of evidence is low. Due to a lack of placebo control, the net efficacy of QG is still uncertain. More high‐quality RCTs are needed to confirm the efficacy and safety of QG in DME.